EFTR

0.00020.00%
JS

Joan S. Brugge

Member of Clinical & Scientific Advisory Board

Dr. Joan S. Brugge, Ph.D. is Scientific Advisor of The Breast Cancer Research Foundation Inc. Dr. Brugge is Co-Director of the Ludwig Center at Harvard Medical School. A graduate of Northwestern University, she did graduate work at the Baylor College of Medicine, completing her PhD in 1975, followed by postdoctoral training at the University of Colorado with Dr. Raymond Erikson. Dr. Brugge has held full professorships at the State University of New York, Stony Brook and the University of Pennsylvania, where she was also named an investigator at the Howard Hughes Medical Institute. From 1992-1997 Dr. Brugge was Scientific Director of the biotechnology company ARIAD. She joined Harvard in 1997 as Professor of Cell Biology, was Chair of Cell Biology from 2004 – 2014 and became Co-Director of the Ludwig Center at Harvard in 2014. Dr. Brugge’s awards include an NIH Merit Award, an American Cancer Society Research Professorship and the Senior Career Recognition Award from the American Society of Cell Biology. She is the recipient of BCRF’s 2015 Jill Rose Award for research excellence. She has been elected to the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine. Dr. Brugge is investigating the mechanisms involved in breast cancer initiation and progression. Her laboratory has utilized three dimensional cultures of normal breast cells and breast tumor cells to recapitulate the organization of cells in their natural context and provide important insights relating to the mechanisms whereby genes that are altered in breast cancer contribute to tumor formation and progression as well as those that mediate resistance to cancer therapies. serves as Venture Partner at Catalio Capital Management, LP. since April 2021. She serves as Chairman at Department of Cell Biology, Harvard Medical School, Boston. Prof. Brugge serves as a Member of Scientific Advisory Board at Frontier Medicines Corporation since July 2021. She serves as a Member of Clinical and Scientific Advisory Board at eFFECTOR Therapeutics, Inc. She serves as Director of the Harvard Ludwig Cancer Center and also a Louise Foote Pfeiffer Professor of Cell Biology at Harvard Medical School. From 1979 to 1988, she was on the faculty of the State University of New York at Stony Brook, as Professor of Microbiology. From 1989 to 1992, Prof. Brugge was a Professor of Microbiology at the University of Pennsylvania School of Medicine and an Investigator of the Howard Hughes Medical Institute. Prior to joining Harvard Medical School, she was the Scientific Director and Vice President for Research of ARIAD Pharmaceuticals, Inc., which she co-founded and was one of Board of Directors. Prof. Brugge joined the faculty of the Harvard Medical School as a Professor in July 1997. She served as a Member of Scientific Advisory Board at Agios Pharmaceuticals, Inc. She received her Bachelor of Arts in Biology with a minor in Chemistry from Northwestern University and her Doctor of Philosophy in Virology from the Baylor College of Medicine. She completed her postdoctoral research at the University of Colorado at Boulder. She is a Member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences and the National Academy of Medicine.

Positions